Clinical trial
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
NCT00524303
Study timeline
Study start (unknown)2007-08-01Date precision: month
Registry last updated2016-11-11
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Neoplasms, Breastunresolved
Interventions
TrastuzumabDRUG · verified · RxNorm: trastuzumab
PaclitaxelDRUG · verified · RxNorm: paclitaxel
FEC75DRUG
LapatinibDRUG · verified · RxNorm: lapatinib
Sponsors & collaborators
GlaxoSmithKlinelead sponsor
Mapped research locations
DallasTexas, United States3HoustonTexas, United States1Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1MiamiFlorida, United States1SeattleWashington, United States1IndianapolisIndiana, United States1DenverColorado, United States1AustinTexas, United States1NorfolkVirginia, United States1El PasoTexas, United States1Pembroke PinesFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00524303 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.